The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity Therapeutics. Data from this study can further be used to explore in a retrospective fashion, sensitivity to other chemotherapeutic drugs previously used in the treatment of their ovarian cancer, to investigate whether or not the DRP® method can predict and confirm the obtained sensitivity to the prior given drugs as well as prospective analyses guiding the Investigators on future treatments.
Study Type
OBSERVATIONAL
Enrollment
60
A DRP is an assay that based on samples from a tumor can predict whether the tumor will respond to a specific drug or not.
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
COMPLETEDOU Health Stephenson Cancer Center
Oklahoma City, Oklahoma, United States
RECRUITINGSwedish Center for Research and Innovation
Seattle, Washington, United States
RECRUITINGBeatson West of Scotland Cancer Centre
Glasgow, Scotland, United Kingdom
ACTIVE_NOT_RECRUITINGGuy's and St Thomas' NHS Foundation Trust, Guy's Hospital
London, United Kingdom
ACTIVE_NOT_RECRUITINGIdentification of ovarian cancer patients with high likelihood of being sensitive to investigational cancer drug
based on FFPE ovarian cancer tissue
Time frame: up to 2 years
Retrospective analysis of whether or not the DRP method can predict and confirm the obtained sensitivity to the prior drugs used in the treatment of ovarian cancer
Time frame: up to 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.